within Pharmacolibrary.Drugs.ATC.R;

model R05CB07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 0.00025,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.03,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0011666666666666668,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R05CB07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Sobrerol is a mucolytic agent used in respiratory medicine to reduce the viscosity of bronchial secretions, facilitating expectoration. It has been marketed in several countries for the treatment of respiratory tract disorders characterized by excessive mucus, although its use has become less common and is not widely approved in the US or many western countries today.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic data for sobrerol with explicit compartmental PK model and parameters could be identified. The following are rough estimations for a typical adult subject based on general principles and available pharmacokinetic reviews of similar mucolytic agents.</p><h4>References</h4><ol><li><p>Lu, CH, et al., &amp; Chu, IM (2022). Design of Oral Sustained-Release Pellets by Modeling and Simulation Approach to Improve Compliance for Repurposing Sobrerol. <i>Pharmaceutics</i> 14(1) –. DOI:<a href=&quot;https://doi.org/10.3390/pharmaceutics14010167&quot;>10.3390/pharmaceutics14010167</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35057064/&quot;>https://pubmed.ncbi.nlm.nih.gov/35057064</a></p></li><li><p>Braga, PC, et al., &amp; Fraschini, F (1983). Pharmacokinetics of Sobrerol in chronic bronchitis. Comparison of serum and bronchial mucus levels. <i>European journal of clinical pharmacology</i> 24(2) 209–215. DOI:<a href=&quot;https://doi.org/10.1007/BF00613819&quot;>10.1007/BF00613819</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6840169/&quot;>https://pubmed.ncbi.nlm.nih.gov/6840169</a></p></li><li><p>Ventura, P, et al., &amp; Serafini, S (1986). Biotransformation of trans-sobrerol. III. Metabolites of 8-hydroxycarvotanacetone in the rat. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 16(4) 317–323. DOI:<a href=&quot;https://doi.org/10.3109/00498258609043534&quot;>10.3109/00498258609043534</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3716453/&quot;>https://pubmed.ncbi.nlm.nih.gov/3716453</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R05CB07;
